Pulmonary tuberculosis is classified as a disease with a
genetic predisposition, and therefore, as with other pathologies related to this group of diseases, by
pulmonary tuberculosis, special importance is given to finding those markers that enable early identification of risk groups, such as skrinnig in general population and relatives of patients with
tuberculosis, which in turn can provide the basis for preventive measures. One of this markers is the level of
genome stability. The aim of this study was a comparative evaluation of the functional parameters of the genome variability in patients with sensitive form of
pulmonary tuberculosis before and
after treatment, and the possibility of its correction with anti-stress
peptide bioregulator -
epitalon. The studies were conducted using short-term mitoge -stimulated cell cultures of TB patients, before and
after treatment. As an
indicator of
genome stability has been studied the frequency of structural and numerical
chromosome aberrations and fragile sites. It is shown, that in intact cultures from patients with
pulmonary tuberculosis, before treatment was significantly higher level of frequency of cells with structural
chromosome aberrations, that still retained after the treatment. As for
epithalon, it appears that was shown a pronounced protective effect
after treatment, on the test of
chromosome aberrations, by reducing both overall mean frequency aberrant cells and indicators for all individuals. In the study of fragility of chromosomes in patients with primary
tuberculosis was found, that in intact cultures, the proportion of cells with chromosomal fragile sites was higher than in control group of healthy individuals, befor and
after treatment. High frequency of
chromosome fragility persisted by treatment with
peptide bioregulator in both cases - before and
after treatment. It is suggested that the identified patterns can be correlated with a high incidence of re- TB.